Co – Delivery of Aceclofenac and Methotrexate Via Lipobirds Renders Therapeutic Effect in Breast Cancer

Abstract

Inflammation and breast cancer are co-related with one another. Inflammation is one of the most rudimentary responses of the body’s self defence mechanism whereas the breast cancer is one of the most complex molecular and morphological diseases. They are mainly initiated by the large number of the immune cells (mast cells), molecular mediator like chemokine, cytokine, vasoactive amines, eicosanoid (Prostaglandins, leukotrienes) and the product of the proteolytic cascade. Inflammation mainly takes place to reduce the effect of injury or to subside the effect of the foreign pathogen and the parasite at the same time playing an integral role in the removal and clearance of the dead cells. Chronic inflammation is mainly associated with the occurrence of complexities like atherosclerosis, cancer etc. Present study surfaces the over-expression of pro-inflammatory markers at molecular level. The use of anti-inflammatory drugs namely Methotrexate and Aceclofenac when loaded onto, lipid-polymer hybrid nano-particles (LPHNPs) plays a crucial role in subsiding pathology induced inflammation. The characterizations of the lipobrids were done containing the different formulation. The size obtained was119.3±0.3; the drug loading efficiencies and the drug loaded size were 94% and 18.8 % respectively. Inflammation is mounted by rapidly dividing cancer cells. We assayed the prepared formulation on the MDA-MB-231 breast cancer cells. We mimic the inflammation in the breast cancer cells by introduction of the LPS and subsequently the amount of inflammation and drug treatment assay was carried out in-vitro. We had also accomplished the drug sensitivity (MTT) assay at three different time points followed by the calculation of the IC50. We observed the sustained release of drug from the lipobrid. In a nut shell the results obtained, proven that this method of drug delivery can open new vistas and be economically more feasible in addressing the inflammatory diseases.